BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Although targeting oncogenic mutations in the BRAF serine/threonine kinase with small molecule inhibitors can lead to significant clinical responses in melanoma, it fails to eradicate tumors in nearly all patients. Successful therapy will be aided by identification of intrinsic mechanisms that prote...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Haq, Rizwan, Yokoyama, Satoru, Hawryluk, Elena B., Jönsson, Göran B., Frederick, Dennie Tompers, McHenry, Kevin, Porter, Dale, Tran, Thanh-Nga, Love, Kevin T., Langer, Robert, Anderson, Daniel G., Garraway, Levi A., Duncan, Lyn McDivitt, Morton, Donald L., Hoon, Dave S. B., Wargo, Jennifer A., Song, Jun S., Fisher, David E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2013
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600451/
https://ncbi.nlm.nih.gov/pubmed/23447565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1205575110
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller